Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
about
Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatmentRabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A.Review of esomeprazole in the treatment of acid disorders.Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.Review article: treatment for gastro-oesophageal reflux disease--lifestyle advice and medication.Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.CYP2C19 genotype and the PPIs--focus on rabeprazole.Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of LifeRole of cytochrome P450 genotype in the steps toward personalized drug therapy.A review of rabeprazole in the treatment of acid-related diseasesEffects of rabeprazole on bone metabolic disorders in a gastrectomized rat modelComparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitisEarly effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizersStronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication ratesProton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A ReviewPreprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparisonSitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.Early effects of oral administration of omeprazole and roxatidine on intragastric pH.Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole.A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers.Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy
P2860
Q33739015-6E32BCBD-F34E-448A-96E0-E4D8AE980733Q33868511-18CD1582-EA93-45F7-8DA4-58A31F86C7B2Q34583603-2273AEA5-E11A-4C46-A659-521198B003B0Q34647904-B107A18A-0914-4C49-B442-7201E410453CQ35040382-3894BA2A-2791-48F6-AE48-291B4D6DA113Q35058137-EB18D87E-2BF8-45BD-8797-C13940A993DBQ35609697-08C74267-3964-4EB6-93E4-4F6748B5F086Q35868527-D69540E9-F6C9-48C7-A965-7298381F5921Q35923954-F9CF3286-231C-4323-83DA-FEC3B6559AA1Q35970047-0F8DB6A0-746E-4E7C-A1E5-1807991B9656Q36322095-36724998-47E1-4A5B-AF6D-C86CB3DE50C4Q36344158-6FF99912-9856-4218-9660-F09F632D1AE9Q36429167-85BEF9E0-8855-4D8D-BEFB-B0051AA883C4Q36441521-F77BD02A-1A16-4020-98A3-2DEE101EEED6Q36661321-B6B0A349-E546-408F-8B59-0F655E903782Q37001665-5C979707-B7F1-490D-A99F-BB85FEE42E99Q37122451-9EF3A776-A6F6-42BB-9436-E32A7A95B6DBQ37240401-F9BB2784-CA14-4DEC-A09D-4F36C03F195DQ37248763-846147A0-D5F4-4733-91AC-76DAE61096B3Q37402476-02791A1E-E9B9-4028-A960-3A21FBE4ACE0Q37578697-8B06A4D0-337F-4A24-84A8-3E2F57EA030FQ38031223-50120257-224E-428D-AD90-DA22DD994A93Q38439983-20647651-7DEB-4A5E-A1B7-4FA97CF98E7DQ39014361-455FF366-9757-4D97-BDD8-B6BE7636E165Q39014376-3B9FADC8-8EC6-4C32-898D-C0548E577CB5Q39115202-547D0C1B-FFB9-4531-956D-E77CA937DEF8Q39386649-FE591BE5-8CCA-453E-AF67-1E95612BE40FQ40174260-53CE3E8F-851C-4ECA-BACE-CD56F4B819C2Q40597694-23544395-56C9-43F6-B0F6-D7786F456902Q41120052-FE9684EE-A8CD-482E-8496-C4F6A1E5D2DFQ41143723-F47C0FBF-B78D-4FB4-907E-212D6E9BA63EQ42868371-53AAF2FE-33F8-47C6-8172-CACD740B7D56Q44545173-65DC34B9-587C-4589-9711-5F7B479C4BC4Q45103019-837D5F3F-CFDA-4902-A7C3-DDE7FEB6429FQ46203790-51559AB6-7687-4243-B5D8-1721297DEA62Q46889718-982D783B-9215-4333-BB36-032E2501A768Q56774960-1174CBA1-CF25-47CE-B697-5B89E92843E7
P2860
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@en
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@nl
type
label
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@en
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@nl
prefLabel
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@en
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@nl
P2093
P2860
P1476
Effects of rabeprazole, lansop ...... YP2C19 extensive metabolizers.
@en
P2093
J Hirakawa
T Ishikawa
Y Fukushima
P2860
P304
P356
10.1046/J.1365-2036.2002.01348.X
P407
P577
2002-10-01T00:00:00Z